Fiera Capital Corp Raises Holdings in Xenon Pharmaceuticals Inc. $XENE

Fiera Capital Corp lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 31.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 686,056 shares of the biopharmaceutical company’s stock after acquiring an additional 166,057 shares during the period. Fiera Capital Corp’s holdings in Xenon Pharmaceuticals were worth $30,749,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. JPMorgan Chase & Co. grew its stake in shares of Xenon Pharmaceuticals by 6.8% during the fourth quarter. JPMorgan Chase & Co. now owns 1,494,032 shares of the biopharmaceutical company’s stock worth $66,963,000 after acquiring an additional 94,999 shares during the last quarter. Capital International Investors boosted its position in Xenon Pharmaceuticals by 7.3% in the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after buying an additional 233,466 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in Xenon Pharmaceuticals by 1.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,226,771 shares of the biopharmaceutical company’s stock valued at $54,984,000 after buying an additional 20,705 shares during the last quarter. State of Wyoming raised its position in Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 350 shares during the last quarter. Finally, TD Asset Management Inc raised its position in Xenon Pharmaceuticals by 135.0% during the 4th quarter. TD Asset Management Inc now owns 38,148 shares of the biopharmaceutical company’s stock worth $1,710,000 after buying an additional 21,918 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Down 1.0%

Xenon Pharmaceuticals stock opened at $51.21 on Tuesday. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $63.95. The stock’s 50 day simple moving average is $55.74 and its two-hundred day simple moving average is $48.68. The firm has a market cap of $4.95 billion, a PE ratio of -10.90 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting the consensus estimate of ($1.17). During the same period in the previous year, the business posted ($0.83) earnings per share. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Jefferies Financial Group set a $100.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Needham & Company LLC cut their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Royal Bank Of Canada increased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $77.20.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director directly owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This represents a 5.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director directly owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 12,572 shares of company stock worth $689,101. 4.07% of the stock is currently owned by corporate insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.